X.am

Immune-related adverse effect/toxicity

irAE. A host of adverse reactions specifically caused by immune checkpoint inhibitors (anti CTLA4, -PD1, -PDL1). May include dermatological reactions, enterocolitis, hepatitis, hypophysitis, thyroiditis, myocarditis, pericardial effusion and/or pneumonitis. See PMID 22614989, 23714523, 24161671, 25861234

Last update : 06/02/2018
 

Causative drugs

2

Immune checkpoint inhibitors (ICPI) - ICPI combinatorial therapy

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic)
X.d X - Systemic reactions, syndromes and conditions
X.d - Lupus - Lupus syndrome (see also Vd)
X.e X - Systemic reactions, syndromes and conditions
X.e - Autoimmunity (see also Xx, Xy)
X.j X - Systemic reactions, syndromes and conditions
X.j - Myositis/polymyositis/DPM/rhabdomyolysis/myopathy
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.am X - Systemic reactions, syndromes and conditions
X.am - Immune-related adverse effect/toxicity
X.aw X - Systemic reactions, syndromes and conditions
X.aw - Connective tissue disease
XI.y XI - Miscellaneous
XI.y - Adrenal suppression
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy
XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-)
XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity
XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation
XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo)
XIX.a XIX - Cytology, biochemistry of BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Ipilimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (see also under ARDS)
I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD)
I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia (or a consistent migratory OP pattern on imaging)
I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component
I.v I - Interstitial/parenchymal lung disease
I.v - Subclinical changes in lung function/PFT
II.b II - Pulmonary edema - ARDS - Acute respiratory failure
II.b - ARDS
V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion
V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative)
VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy
IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis
IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause ARF)
X.a X - Systemic reactions, syndromes and conditions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome)
X.e X - Systemic reactions, syndromes and conditions
X.e - Autoimmunity (see also Xx, Xy)
X.g X - Systemic reactions, syndromes and conditions
X.g - Hypersensitivity reaction (may involve skin, throat and/or airways)
X.k X - Systemic reactions, syndromes and conditions
X.k - Granulomatous sarcoid-like thoracic and/or extrathoracic reaction
X.l X - Systemic reactions, syndromes and conditions
X.l - Systemic granulomatosis other than Xk
X.o X - Systemic reactions, syndromes and conditions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet)
X.am X - Systemic reactions, syndromes and conditions
X.am - Immune-related adverse effect/toxicity
XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis, pericardial effusion, tamponade
XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis
XV.c XV - Pulmonary pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy
XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection
XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary
3